Evidence-based decision-making in Asia-Pacific with rapidly changing health-care systems: Thailand, South Korea, and Taiwan

Value in Health

Volumn 12, Issue SUPPL. 3, 2009, Pages S4-

  Jirawattanapisal, Thidaporn ^a   Kingkaew, Pritaporn ^a   Lee, Tae Jin ^b   Yang, Ming Chin ^c  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b Seoul National University   (South Korea)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Economic analysis; Economic evaluation; Economic outcome; Health economics; Health care decision makers

Indexed keywords

ANTIBIOTIC AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; CLOPIDOGREL; DISINFECTANT AGENT; DOCETAXEL; EFAVIRENZ; ERLOTINIB; ESSENTIAL DRUG; GENERIC DRUG; IMATINIB; LETROZOLE; LOPINAVIR PLUS RITONAVIR; NEW DRUG; NON PRESCRIPTION DRUG; RADIOACTIVE MATERIAL; VACCINE;

BIOEQUIVALENCE; DECISION MAKING; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG QUALITY; DRUG SAFETY; EVIDENCE BASED PRACTICE; HEALTH CARE SYSTEM; HUMAN; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW; SOUTH KOREA; TAIWAN; THAILAND;

EID: 72149102681     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2009.00620.x     Document Type: Review

References (13)

1. Amrumpai Y. Identifying Safety Indicators of New Drug Safety Monitoring Programme (SMP) in Thailand. Bangkok : Chulalongkorn University, 2001.
2. Division of Drug Control. Safety Monitoring Program. Nonthaburi, Thailand : The Food and Drug Administration, 2001.
3. The Legal Group of Thai Food and Drug Administration. A Compilation of Law on Food and Drug. Nonthaburi, Thailand : The Food and Drug Administration, 1994.
4. Kunaratanapruk S. The Food and Drug Administration Notification on Registration of New Drugs and New Generic Drugs. Nonthaburi, Thailand : The Food and Drug Administration, 2004.
5. Committee of Drug Bill. Drug Bill. Nonthaburi : Ministry of Public Health, 2007.
6. The Adverse Drug Reaction Monitoring Center. ADR alert: withdrawal of market authorization of lumiracoxib. Available from: http://www.fda.moph.go.th/ apr/newsletter/lumiracoxib02.pdf [Accessed April 20, 2008 M, Wibulpolprasert S, Yamphayak N, et al. Thai Drug System. Bangkok : The College of Public Health Chulalongkorn University, 1997.
7. International Society for Pharmacoeconomics and Outcome Research. Pharmacoeconomics guideline around the world. Available from: http://www.ispor.org/PEguidelines/index.asp [Accessed June 4, 2009 HL, Chern HD, Chu ML. Reinventing drug regulation in the Asia Pacific region: Taiwan's experience and a vision for the region. Drug Inf J 2003 37 (November S41 8.
8. Division of Health Technology Assessment. Reimbursement review process. Available from: http://www.cde.org.tw/hta/main.htm [Accessed June 4, 2009
9. YC, Yang MC, Huang YT, et al. Impacts of the cost containment strategies on pharmaceutical expenditures of the National Health Insurance in Taiwan, 1996-2003. Pharmacoeconomics 2006 24 : 891 902.
10. The National Health Insurance in Taiwan. The Report of Total Health Care and Drug Expenditures in NHI: 1998-2007, as of May 2008. Taipei : Bureau of National Health Insurance, 2005.
11. Chongtrakul P, Sumpradit N, Yoongthong W. ISafE and the evidence-based approach for essential medicines selection in Thailand. Essent Drugs Monit 2005 34 : 18 19.
12. Teerawattananon Y, Tangcharoensathien V, Tantivess S, et al. Health sector regulation in Thailand: recent progress and the future agenda. Health Policy 2003 63 : 323 338.
13. Faramnuayphol P, Ekachampaka P, Taverat R, et al. Health service systems in Thailand. In : Wibulpolprasert S, ed. Thailand Health Profile 2005-2007. Nonthaburi, Thailand : The Ministry of Public Health, 2007.